Antiallergic and anti-inflammatory action of tioxamast in rats. II. Anti-inflammatory action in vivo.

Abstract

Tioxamast is an antiallergic drug that inhibits anaphylaxis in various models in rats, and it inhibits the release and synthesis of certain mediators of inflammation [see Tarayre et al., this issue]. Here we report that the drug also has an anti-inflammatory effect in vivo in various nonimmunological models in rats. It reduces zymosan-induced inflammation in the paw and pleural cavity, starting at doses from 1.5625 to 3.125 mg/kg given intraperitoneally. In pleurisy, tioxamast lowers the concentration of leukotriene B4 (LTB4) in the exudate, at doses from 50 mg/kg i.p. Also, at doses from 12.5 mg/kg i.p., the compound reduced PAF-acether-induced pleurisy and the concentrations of LTB4 and peptidoleukotrienes in the exudate. An anti-inflammatory action against carrageenin-induced edema of the paw was seen only at doses of 50 mg/kg i.p. or more. The anti-inflammatory and antiallergic effect of tioxamast makes it a potentially useful drug in the treatment of allergies in humans.

• Authors: J P Tarayre, M Aliaga, M Barbara, N Tisseyre, V Caillol, A Delhon, F Bruniquel, X N'Guyen, L Puech, J Tisné-Versailles
• Journal: International archives of allergy and applied immunology (Int Arch Allergy Appl Immunol) Vol. 92 Issue 1 Pg. 77-81 ( 1990) ISSN: 0020-5915 [Print] Switzerland
• PMID: 2246078 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Histamine Antagonists
• Platelet Activating Factor
• Zymosan
• tioxamast
• Oxamic Acid

Topics

• Animals
• Anti-Inflammatory Agents, Non-Steroidal (pharmacology)
• Edema (drug therapy)
• Histamine Antagonists (pharmacology)
• Male
• Oxamic Acid (analogs & derivatives, pharmacology)
• Platelet Activating Factor (pharmacology)
• Pleurisy (drug therapy)
• Rats
• Rats, Inbred Strains
• Zymosan (pharmacology)